NASDAQ:CGEN - Compugen Stock Price, Forecast & News

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Thursday, February, 20th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01. View Compugen's Earnings History.

Compugen is scheduled to release their next quarterly earnings announcement on Monday, May 18th 2020. View Earnings Estimates for Compugen.

2 brokerages have issued twelve-month price objectives for Compugen's stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Compugen's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for Compugen.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

Headlines about CGEN stock have been trending very negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Compugen earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Compugen.

Some companies that are related to Compugen include Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI) and Adverum Biotechnologies (ADVM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), Pluristem Therapeutics (PSTI), Sarepta Therapeutics (SRPT), Canopy Growth (CGC), Catalyst Pharmaceuticals (CPRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), REDHILL BIOPHAR/S (RDHL) and AT&T (T).

Compugen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (17.50%), Nikko Asset Management Americas Inc. (15.89%), Renaissance Technologies LLC (1.42%), Taylor Frigon Capital Management LLC (1.41%), Rothschild Investment Corp IL (0.67%) and Defender Capital LLC. (0.59%).

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Benjamin F. Edwards & Company Inc., Jane Street Group LLC, UBS Group AG, Phoenix Holdings Ltd. and Raymond James & Associates.

CGEN stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., ARK Investment Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Oxford Asset Management LLP, ProShare Advisors LLC and CWS Financial Advisors LLC.

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $9.12.

Compugen has a market capitalization of $467.79 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.

The official website for Compugen is http://www.cgen.com/.

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]